Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: A sialometrical study

Bone Marrow Transplantation

Volumn 23, Issue 10, 1999, Pages 1007-1011

  Nagler, R M ^a   Nagler, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

GVHD; Pilocarpine hydrochloride; Saliva; Salivary glands; Sialometrical analysis; Xerostomia

Indexed keywords

PILOCARPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLOW RATE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PAROTID GLAND; PRIORITY JOURNAL; SALIVATION; SIDE EFFECT; SUBMANDIBULAR GLAND; SWEATING; XEROSTOMIA;

EID: 0032971196     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701752     Document Type: Article

References (29)

1. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood 1982; 62: 941-964.
2. Slavin S, Nagler A. New developments in bone marrow transplantation. Curr Opin Oncol 1991; 3: 254-271.
3. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 266-276.
4. Peszkowski MJ, Fujiwara K, Warfvinge G, Larsson A. Experimental graft-versus-host disease in the (BN × LEW) F1 rat hybrid as a model for autoimmune disease. Study of early adenitis in lachrymal and salivary glands. Autoimmunity 1996; 24: 101-111.
5. Hiroki A, Nakamura S, Shinohara M et al. A comparison of glandular involvement between chronic graft-versus-host disease and Sjögren's syndrome. Int J Oral Maxillofac Surg 1996; 25: 298-307.
6. Gratwhol AA, Mantsopoulos HM, Chused TM et al. Sjögren-like syndrome after allogeneic bone marrow transplantation. Ann Intern Med 1977; 87: 703-706.
7. Sorenson I, Ussing AP, Prauss U et al. Histopathological changes in exocrine glands of murine transplantation chimeras. I. The development of Sjörgen's syndrome-like changes secondary to GVHD-induced lupus syndrome. Autoimmunity 1992; 11: 261-271.
8. Nagler A, Barak V, Slavin S. The role of cytokines in graft-versus-host reactions/bone marrow rejection. In: Puri RK, Aggarwal BB (eds). Human Cytokines: Their Role in Disease and Therapy. Blackwell Publications: Oxford, 1995, pp 153-161.
9. Sale GE, Shulman HM, Schubert MM et al. Oral and ophthalmic pathology of graft-versus-host disease in man: predictive value of lip biopsy. Hum Pathol 1981; 12: 1022-1030.
10. Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs salivary gland changes in lip biopsies in the diagnosis of chronic graft-versus-host disease. Arch Pathol Lab Med 1989; 113: 932-934.
11. Norhagen G, Engstrom PE, Bjorkstrand B et al. Salivary and serum immunoglobulins in recipients of transplanted allogeneic and autologous bone marrow. Bone Marrow Transplant 1994; 14: 229-234.
12. Nagler R, Marmary Y, Krausz Y et al. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1996; 17: 219-224.
13. Izutsu KT, Sullivan KM, Schubert MM et al. Disordered salivary immunoglobulin secretion and sodium transport in human disease graft-versus-host disease. Transplantation 1983; 35: 441-446.
14. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in an animal model of chronic graft-versus-host disease. Arch Otolaryngol Head Neck Surg 1996; 122: 1057-1060.
15. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in a murine model of acute graft-versus-host disease (aGVHD). Head Neck 1998; 20: 58-62.
16. Mandel ID. The function of saliva. J Dent Res 1987; 66: 623-627.
17. Wynn RL. Oral pilocarpine (salagen) - a recently approved salivary stimulant. General Dentistry 1996; 44: 26-30.
18. Wiseman L, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995; 49: 143-155.
19. Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. New Engl J Med 1993; 329: 390-395.
20. Greenspan D, Daniels TE. Effectiveness of pilocarpine in post-radiation xerostomia. Cancer 1987; 59: 1123-1125.
21. Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986; 61: 243-248.
22. Fox PC, van der Ven PF, Sonies BC et al. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 1985; 110: 519-525.
23. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1991; 72: 545-549.
24. Fox PC. Systemic therapy of salivary gland hypofunction. J Dent Res 1987; 66: 689-692.
25. Tabak LA, Levina MJ, Mandel ID, Ellison SA. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol 1982; 11: 1-17.
26. Singhal S, Mehta J, Rattenbury H et al. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 1995; 85: 1147-1148.
27. Singhal S, Powles R, Treleaven J et al. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997; 24: 539-543.
28. 14C-mannosamine into submandibular mucin of the mouse. Biochim Biophys Acta 1984; 798: 103-110.
29. Gallagher JT, Hall RL, Phipps RJ et al. Mucus-glycoproteins (mucins) of the cat trachea: characterisation and control of secretion. Biochim Biophys Acta 1986; 886: 243-254.